Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19
Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
SENTAD-COVID Study is an adaptive, prospective, multicentric, open-label, and randomized
controlled clinical trial involving hospitalized adult patients with confirmed coronavirus
disease 2019 (COVID-19) infection during the outbreak in Abu Dhabi, 2020. The patients were
randomly allocated in a parallel assignment involving two groups of participants: Group A
(Experimental arm): autologous non-hematopoietic peripheral blood stem cells (NHPBSC) therapy
as add-on COVID-19 standard care, or Group B (No investigational intervention arm): COVID-19
standard care. Standard care is defined as per the "UAE National Guidelines for Clinical
Management and Treatment of COVID-19". SENTAD-COVID Study was conducted in the Sheikh Khalifa
Medical City (SKMC) of Abu Dhabi, as Primary Care Clinical Trial Unit, while the cell
processing and investigational product formulation were completed by Abu Dhabi Stem Cells
Center (ADSCC), according to Good Laboratory Practices (GLPs) and Good Manufacturing
Practices (GMPs).